Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
26CA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.63 - €6.25
Previous CloseN/A
Volume0.00
Average Volume (3M)1.30K
Market Cap
$1.85B
Enterprise Value€3.03B
Total Cash (Recent Filing)$153.66M
Total Debt (Recent Filing)$535.32M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 07, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding945,254,700
10 Day Avg. Volume730
30 Day Avg. Volume1,304
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.64
Enterprise Value/Revenue53.62
Enterprise Value/Gross Profit53.80
Enterprise Value/Ebitda-16.63
Forecast
1Y Price Target
$6.87Price Target Upside257.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated data from the QUILT-3.032 trial showed that ANKTIVA plus BCG led to a 58.2% disease-free survival rate at 12 months in patients with BCG-unresponsive NMIBC and papillary disease without CIS.
Earnings GrowthANKTIVA's sales reached $26.4M, reflecting 60% quarter-over-quarter growth, driven by increasing adoption in U.S. urology practices.
Regulatory ApprovalsThe U.K. approval marks a key international milestone for Anktiva, representing a significant step in ImmunityBio's global strategy and affirming the strength of Anktiva’s underlying data.
Bears Say
Regulatory ChallengesThe FDA raised concerns about the single-arm design of the QUILT-3.032 Cohort B study during the Type A meeting regarding ANKTIVA’s supplemental BLA.
Regulatory DelaysImmunityBio announced it received a surprising Refusal to File (RTF) letter from the FDA regarding its supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC patients with papillary-only disease.
Regulatory UncertaintyThe RTF letter introduces regulatory uncertainty, despite the identical treatment protocol between CIS and papillary cohorts.
ImmunityBio News
26CA FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.63 and its highest was €6.25 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $1.85B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Nov 07, 2025 which is in 76 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Aug 05, 2025. The company reported -€0.086 earnings per share for the quarter, beating the consensus estimate of -€0.093 by €0.007.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.09.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 945,254,700 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -€0.086 in its last earnings report, beating expectations of -€0.093. Following the earnings report the stock price went down -0.48%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in DE:26CA
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.87 (257.78% Upside)
$6.87 (257.78% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 75%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.51%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
26CA Stock 12 Month Forecast
Average Price Target
€6.87
▲(257.78% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
74.12% Insiders
2.92%
Mutual Funds
0.30% Other Institutional Investors
18.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---